La Renon recently welcomed an investment from ChrysCapital, a milestone that aligns them with prestigious names in the Indian healthcare industry like Intas Pharma and Mankind Pharma. Pankaj Singh, the founder and chairman of La Renon Healthcare, expressed gratitude towards ChrysCapital for recognizing their strengths, further fueling their goal of making significant strides in the pharmaceutical sector in the coming years. Additionally, he acknowledged the support from Peak XV Partners and A91 Emerging Fund LLP, long-standing partners who have contributed to La Renon's growth journey.
Peak XV Partners, previously known as Sequoia India, has been involved with La Renon since 2015, emphasizing a long-term commitment to the company's progress. This recent partnership with ChrysCapital signifies a strategic move for La Renon, highlighting their position as a rapidly expanding entity in the field of domestic formulations in India. The transaction was facilitated by Investment Bank o3 Capital, demonstrating a collaborative effort in securing this crucial investment.
Established in 2007, La Renon prides itself on its exceptional growth within the Indian formulations landscape, particularly in specialized therapeutic areas such as nephrology, neurology, and gastroenterology. Kshitij Sheth, the managing director of ChrysCapital, echoed the sentiments of excitement regarding this investment, commending La Renon's achievements in various chronic therapeutic segments. ChrysCapital's track record in the pharmaceutical sector, including successful exits like Mankind Pharma, speaks to their expertise and strategic investments to foster growth and profitability.